Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone
Veri Medtech (VRHI) announced reaching a significant milestone of $100 million in cumulative revenue since its 2017 inception, with Q1 2025 revenue of $3.3 million. The healthcare technology platform has achieved several key milestones, including reaching up to 400,000 patients and 400 physicians on its network. The company has recently relaunched two key platforms: Veriheal.com and DosePop.com, as part of its telehealth diversification strategy. VRHI has also retained a PCAOB auditor in preparation for a potential uplisting. The company positions itself to compete with LifeMD, Ro, and HIMS in the $114 billion telehealth market through its Infinite Wellness Loop platform.
Veri Medtech (VRHI) ha annunciato di aver raggiunto un traguardo importante con un fatturato cumulativo di 100 milioni di dollari dalla sua fondazione nel 2017, registrando un fatturato di 3,3 milioni di dollari nel primo trimestre del 2025. La piattaforma tecnologica sanitaria ha conseguito diversi risultati chiave, tra cui il coinvolgimento di 400.000 pazienti e 400 medici nella sua rete. Recentemente l’azienda ha rilanciato due piattaforme fondamentali: Veriheal.com e DosePop.com, nell’ambito della sua strategia di diversificazione nel telehealth. VRHI ha inoltre ingaggiato un revisore PCAOB in vista di una possibile quotazione su un mercato superiore. L’azienda si posiziona per competere con LifeMD, Ro e HIMS nel mercato del telehealth da 114 miliardi di dollari grazie alla sua piattaforma Infinite Wellness Loop.
Veri Medtech (VRHI) anunció haber alcanzado un hito significativo con 100 millones de dólares en ingresos acumulados desde su creación en 2017, reportando ingresos de 3,3 millones de dólares en el primer trimestre de 2025. La plataforma tecnológica de salud ha logrado varios hitos clave, incluyendo llegar a 400,000 pacientes y 400 médicos en su red. Recientemente, la compañía relanzó dos plataformas clave: Veriheal.com y DosePop.com, como parte de su estrategia de diversificación en telemedicina. VRHI también ha contratado a un auditor PCAOB en preparación para una posible subida de cotización. La empresa se posiciona para competir con LifeMD, Ro y HIMS en el mercado de telemedicina de 114 mil millones de dólares a través de su plataforma Infinite Wellness Loop.
Veri Medtech (VRHI)는 2017년 설립 이후 누적 매출 1억 달러라는 중요한 이정표를 달성했으며, 2025년 1분기 매출은 330만 달러를 기록했다고 발표했습니다. 이 헬스케어 기술 플랫폼은 40만 명의 환자와 400명의 의사를 네트워크에 포함시키는 등 여러 주요 성과를 이루었습니다. 최근 회사는 원격의료 다각화 전략의 일환으로 Veriheal.com과 DosePop.com 두 개의 핵심 플랫폼을 재출시했습니다. 또한 VRHI는 상장 준비를 위해 PCAOB 감사인을 선임했습니다. 회사는 Infinite Wellness Loop 플랫폼을 통해 1140억 달러 규모의 원격의료 시장에서 LifeMD, Ro, HIMS와 경쟁할 위치에 있습니다.
Veri Medtech (VRHI) a annoncé avoir atteint un jalon important avec un chiffre d'affaires cumulé de 100 millions de dollars depuis sa création en 2017, avec un chiffre d'affaires de 3,3 millions de dollars au premier trimestre 2025. La plateforme technologique de santé a réalisé plusieurs étapes clés, notamment en réunissant jusqu’à 400 000 patients et 400 médecins dans son réseau. La société a récemment relancé deux plateformes clés : Veriheal.com et DosePop.com, dans le cadre de sa stratégie de diversification en télésanté. VRHI a également engagé un auditeur PCAOB en préparation d’une éventuelle montée en bourse. L’entreprise se positionne pour concurrencer LifeMD, Ro et HIMS sur le marché de la télésanté de 114 milliards de dollars grâce à sa plateforme Infinite Wellness Loop.
Veri Medtech (VRHI) gab bekannt, einen bedeutenden Meilenstein mit 100 Millionen US-Dollar kumulativem Umsatz seit der Gründung im Jahr 2017 erreicht zu haben, mit einem Umsatz von 3,3 Millionen US-Dollar im ersten Quartal 2025. Die Healthcare-Technologieplattform hat mehrere wichtige Meilensteine erreicht, darunter die Einbindung von 400.000 Patienten und 400 Ärzten in ihr Netzwerk. Das Unternehmen hat kürzlich zwei wichtige Plattformen, Veriheal.com und DosePop.com, im Rahmen seiner Diversifizierungsstrategie im Bereich Telemedizin neu gestartet. VRHI hat zudem einen PCAOB-Wirtschaftsprüfer engagiert, um sich auf eine mögliche Börsenaufstufung vorzubereiten. Das Unternehmen positioniert sich mit seiner Infinite Wellness Loop-Plattform, um im 114 Milliarden US-Dollar schweren Telemedizinmarkt mit LifeMD, Ro und HIMS zu konkurrieren.
- Achieved $100 million cumulative revenue milestone since 2017
- Growing network with 400,000 patients and 400 physicians
- Strategic expansion through relaunch of two platforms: Veriheal.com and DosePop.com
- Preparation for uplisting with PCAOB auditor retention
- Q1 2025 revenue of $3.3M suggests relatively small quarterly revenue compared to established competitors
- Faces significant competition from established players like LifeMD, Ro, and HIMS
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology platform, announced today that
Additional Key Accomplishments:
- Retained PCAOB Auditor (in preparation for uplisting)
- Announced up to 400,000 Patients Milestone
- Announced up to 400 Physicians Milestone
- Relaunched Veriheal.com
- Relaunched DosePop.com (Executing On telehealth healthcare technology diversification strategy)
“Veri Medtech (VRHI) continues to be a market leading healthcare platform enabling patients and doctors to seamless connect. In Q1, Veri Medtech (VRHI) successfully relaunched its industry-leading Veriheal.com healthcare technology platform, while simultaneously executing on strategic diversification via its relaunch also of DosePop.com. LifeMD, Ro and HIMS are key competitive barometers of the future of healthcare, and with
About Veri Medtech (OTC Markets: VRHI): Veri Medtech is a publicly-traded healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With a strong integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models. With a commitment to innovation and patient-centric care, Veri MedTech continues to expand its services and reach, aiming to make personalized healthcare more accessible and effective for all. For more information, please visit: www.VeriMedTech.com
About Veriheal: Veriheal, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”) is a healthcare technology company on a mission to help real people get real medicine. For more information, please visit: www.Veriheal.com
About DosePop: DosePop, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), provides a one-stop healthcare technology platform for mental and physical health, all designed to empower you to take charge of your well-being. From weight loss solutions to anti-aging, our treatments are backed by science and administered by licensed professionals. For more information, please visit: www.DosePop.com
About Global Telemedicine: The global telemedicine market size was valued at USD 114.98 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of
Forward Looking Statements: Cautionary Note Regarding Forward-Looking Statements: This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Veri Medtech (OTC: "VRHI") and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
PR Contact: pr@verimedtech.com
FAQ
What is Veri Medtech's (VRHI) total revenue since inception?
How much revenue did VRHI generate in Q1 2025?
What are the key milestones achieved by Veri Medtech (VRHI)?
Who are Veri Medtech's main competitors in the telehealth market?
What is the size of the telehealth market opportunity according to VRHI?
